The African Medicines Agency (AMA) has taken further steps towards establishing a coordinated regulatory framework for medical products across Africa, including the development of a dedicated technical structure for regulatory inspections.
On 26 October 2026, during its inaugural AMA Week in Kigali, Rwanda, the Agency inaugurated seven technical committees established under the AMA Treaty. The committees are intended to provide independent scientific and technical advice across key areas of medical product regulation, supporting cooperation between the AMA and national regulatory authorities.
Their areas of responsibility include the evaluation of medicines, vaccines and biological products; clinical trials oversight; market intelligence and control; quality-control laboratories; vigilance; regulatory inspections; and medical devices, diagnostics and emerging technologies. Members were selected through an open, competitive and merit-based process and serve as independent experts.
The establishment of the Committee on Regulatory Inspections is particularly relevant to the development of pharmaceutical quality oversight across the continent. It provides a dedicated expert structure for work related to regulatory inspections within AMA’s broader mandate to strengthen cooperation and promote more consistent regulatory practices among national authorities.
AMA launches two new hubs to support regulatory development
On 27 October, AMA Week also saw the launch of two institutional initiatives: the Regulatory Innovation and Manufacturing Readiness Hub and the Capacity Strengthening Hub.
The Regulatory Innovation and Manufacturing Readiness Hub is intended to provide manufacturers and innovators with earlier access to regulatory advice and clearer channels for engagement with the Agency. Its activities are designed to support local pharmaceutical manufacturing and help companies understand regulatory expectations relating to product quality, safety and efficacy.
The initiative is particularly relevant to manufacturers seeking to develop products for multiple African markets. It is intended to facilitate earlier regulatory engagement and support cooperation between AMA and national regulatory authorities, helping manufacturers navigate regulatory requirements across different markets.
The Capacity Strengthening Hub will focus on developing regulatory expertise across national authorities and regional organisations. Its work is intended to support regulatory capacity development, professional expertise and cooperation between regulatory institutions across the continent.
AMA takes over continental regulatory harmonisation programmes
The latest developments follow the transfer of the African Medicines Regulatory Harmonisation (AMRH) and African Union Smart Safety Surveillance (AU3S) programmes from the African Union Development Agency–NEPAD (AUDA-NEPAD) to AMA, completed in January 2026.
The transition included the transfer of technical, financial, digital, operational, legal and regulatory assets and functions. It formally placed these continental programmes within AMA’s institutional framework, consolidating responsibility for their continued implementation.
Cooperation with the World Health Organization (WHO) is another important component of this process. In May 2026, WHO and AMA signed a Framework Agreement for Collaboration, followed by a five-year joint operational plan covering regulatory harmonisation, capacity development, safety surveillance and support for local manufacturing.
The 11th African Medicines Regulators Conference, co-convened by WHO and AMA during the inaugural Agency Week, provided an additional platform for advancing regulatory harmonisation, convergence and reliance.
According to WHO, ten African national regulatory authorities have now reached Maturity Level 3 under its Global Benchmarking Tool (GBT). This level indicates that an authority has a stable, well-functioning and integrated regulatory system.
National authorities remain central to Africa’s medicines regulation
AMA’s mandate is to strengthen and coordinate regulatory systems across the continent, promote reliance and mutual recognition, and support the harmonisation of regulatory requirements.
The Agency does not replace national regulatory authorities. Decisions on marketing authorisation remain within the competence of national authorities, while AMA provides a continental framework for scientific cooperation, regulatory coordination and capacity development.
The inauguration of the technical committees and launch of the two hubs therefore represent steps towards a more coordinated regulatory environment rather than the immediate establishment of a single continental inspection or marketing authorisation system.
For pharmaceutical manufacturers operating across African markets, these developments could provide more structured channels for regulatory engagement, greater opportunities for cooperation between national authorities and a more coordinated approach to preparing products for multiple markets.


